Citations

Clear

6273 citation(s) found for "To, Andrew".

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)
Marks, David I. , Paietta, Elisabeth , Moorman, Anthony V. , Richards, Susan , Buck, Georgina , Dewald, Gordon W., Ferrando, Adolfo A. , Goldstone, Anthony H., Ketterling, Rhett P. , Litzow, Mark R. , Luger, Selina M. , McMillan, Andrew , Mansour, Marc R. , Rowe, Jacob M. , Tallman, Martin S. , Fielding, Adele K. , Lazarus, Hillard M. , Ketterling, Rhett P

Mayo Clinic

Blood | October 15, 2009 | Volume: 114 | Issue: 25 | Pages: 5136-5145

10.1182/blood-2009-08-231217 | PMID 19828704 Get It

AbstractThe biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood. We present here the clinical and biologic features of 356 patients treated uniformly on the prospective trial (UKALL XII/ECOG 2993) with the aim of describing the outcome and identifying prognostic factors. Complete remission was obtained in 94% of patients, and 48% survived 5 years. Positivity of blasts for CD1a and lack of expression of CD13 were associated with better survival (P = .01 and < .001, respectively). NOTCH1 and CDKN2A mutations were seen in 61% and 42% of those tested. Complex cytogenetic abnormalities were associated with poorer survival (19% vs 51% at 5 years, P = .006). Central nervous system involvement at diagnosis did not affect survival (47% vs 48%, P = not significant). For 99 patients randomized between autograft and chemotherapy, 5-year survival was 51% in each arm. Patients with a matched sibling donor had superior 5-year survival to those without donors (61% vs 46%, χ2, P = .02); this was the result of less relapse (25% vs 51% at 5 years, P < .001). Only 8 of 123 relapsed patients survive. This study provides a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patients with poor-prognosis T-cell ALL.
Hypertension during Pregnancy is Associated with Coronary Artery Calcium Independent of Renal Function
Cassidy‐Bushrow, Andrea E. , Bielak, Lawrence F. , Sheedy, Patrick F. , Garovic, Vesna D. , Peyser, Patricia A. , Rule, Andrew D. , Turner, Stephen T. , Garovic, Vesna D

Mayo Clinic

Journal of Women's Health | September 28, 2009 | Volume: 18 | Issue: 10 | Pages: 1709-1716

10.1089/jwh.2008.1285 | PMID 19785565 Get It

Background: Hypertension during pregnancy (HDP) increases the risk of future coronary heart disease (CHD), but it is unknown whether this association is mediated by renal injury. Reduced renal function is both a complication of HDP and a risk factor for CHD. Methods: Logistic regression models were fit to examine the association between a history of HDP and the presence and extent of coronary artery calcification (CAC), a measure of subclinical coronary artery atherosclerosis, in 498 women from the Epidemiology of Coronary Artery Calcification Study (mean age 63.3 ± 9.3 years). Results: Fifty-two (10.4%) women reported a history of HDP. After adjusting for age at time of study participation, HDP was associated with increased serum creatinine later in life ( p = 0.014). HDP was positively associated with the presence of CAC after adjusting for age at time of study participation (OR = 2.7, 95% CI 1.4-5.4). This association was slightly attenuated with adjustment for body size and blood pressure (OR = 2.4, 95% CI 1.2-4.9) but was not further attenuated with adjustment for serum creatinine and urinary albumin/creatinine ratio (OR = 2.6, 95% CI 1.3-5.3). Results were similar for CAC extent. Conclusions: HDP may increase a woman's risk of future CHD beyond traditional risk factors and renal function. Women with a history of HDP should be monitored for potential increased risk of CHD as they age.
Characterization of PCEng2, a β-1,3-Endoglucanase Homolog in Pneumocystis carinii with Activity in Cell Wall Regulation
Villegas, Leah R., Kottom, Theodore J. , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | September 25, 2009 | Volume: 43 | Issue: 2 | Pages: 192-200

10.1165/rcmb.2009-0131oc | PMID 19783787 Get It

Abstract Pneumocystis jirovecii pneumonia is an opportunistic fungal infection that causes severe respiratory impairment in immunocompromised patients. The viability of Pneumocystis organisms is dependent on the cyst cell wall, a structural feature that is regulated by essential cell wall–associated enzymes. The formation of the glucan-rich cystic wall has been previously characterized, but glucan degradation in the organism—specifically, degradation during trophic excystment—is not yet fully understood. Most studies of basic Pneumocystis biology have been conducted in Pneumocystis carinii or Pneumocystis murina, the varieties of this genus that infect rats and mice, respectively. Furthermore, all known treatments for P. jirovecii were initially discovered through studies of P. carinii. Accordingly, in this study, we have identified a P. carinii β-1,3-endoglucanase gene (PCEng2) that is demonstrated to play a significant role in cell wall regulation. The cDNA sequence contained a 2.2-kb open reading frame with conserved amino acid domains homologous to similar fungal glycosyl hydrolases (GH family 81). The gene transcript showed up-regulation in cystic isolates, and the expressed protein was detected within both cyst and trophic forms. Complementation assays in Eng2-deleted Saccharomyces cerevisiae strains showed restoration of the cell wall separation defect during proliferation, demonstrating the importance of PCEng2 protein. during fungal growth. These findings suggest that regulation of cyst cell wall β-glucans is a fundamental process during completion of the Pneumocystis life cycle.
Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
Horning, Sandra J., Wiseman, Gregory A., McMillan, Alex, Swinnen, Lode J., Advani, Ranjana H. , Gascoyne, Randy D. , Quon, Andrew , Juweid, Malik E. , Schöder, Heiko , Advani, Ranjana H

Mayo Clinic

Blood | September 18, 2009 | Volume: 115 | Issue: 4 | Pages: 775-777

10.1182/blood-2009-08-234351 | PMID 19767508 Get It

Abstract Positive interim positron emission tomography (PET) scans are thought to be associated with inferior outcomes in diffuse large B-cell lymphoma. In the E3404 diffuse large B-cell lymphoma study, PET scans at baseline and after 3 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone were centrally reviewed by a single reader. To determine the reproducibility of interim PET interpretation, an expert panel of 3 external nuclear medicine physicians visually scored baseline and interim PET scans independently and were blinded to clinical information. The binary Eastern Cooperative Oncology Group (ECOG) study criteria were based on modifications of the Harmonization Criteria; the London criteria were also applied. Of 38 interim scans, agreement was complete in 68% and 71% by ECOG and London criteria, respectively. The range of PET+ interim scans was 16% to 34% (P = not significant) by reviewer. Moderate consistency of reviews was observed: κ statistic = 0.445 using ECOG criteria, and κ statistic = 0.502 using London criteria. These data, showing only moderate reproducibility among nuclear medicine experts, indicate the need to standardize PET interpretation in research and practice. This trial was registered at www.clinicaltrials.gov as #NCT00274924.
Spotlight on the Future of Scientific Publication
Petzold, Andrew M. , Clark, Karl J. , Ekker, Stephen C. , Ekker, Stephen C , Clark, Karl J

Mayo Clinic

Zebrafish | September 17, 2009 | Volume: 6 | Issue: 3 | Pages: 215-217

10.1089/zeb.2009.9992 | PMID 19761376 Get It

Aspirin for the Primary Prevention of Cardiovascular Events
Calvin, Andrew D. , Aggarwal, Niti R., Murad, M. Hassan , Shi, Qian , Elamin, Mohamed B., Geske, Jeffrey B. , Fernández-Balsells, Mercè , Lampropulos, Julianna F., Erwin, Patricia J., Smith, Steven A., Montori, Víctor M. , Albuquerque, Felipe N. , Murad, M Hassan , Montori, Victor M , Shi, Qian , Geske, Jeffrey B , Calvin, Andrew D

Mayo Clinic

Diabetes Care | September 9, 2009 | Volume: 32 | Issue: 12 | Pages: 2300-2306

10.2337/dc09-1297 | PMID 19741185 Get It

OBJECTIVE The negative results of two randomized controlled trials (RCTs) have challenged current guideline recommendations for using aspirin for primary prevention of cardiovascular events among patients with diabetes. We therefore sought to determine if the effect of aspirin for primary prevention of cardiovascular events and mortality differs between patients with and without diabetes. RESEARCH DESIGN AND METHODS We conducted a systematic search of MEDLINE, EMBASE, Cochrane Library, Web of Science, and Scopus since their inceptions until November 2008 for RCTs of aspirin for primary prevention of cardiovascular events. Blinded pairs of reviewers evaluated studies and extracted data. Random-effects meta-analysis and Bayesian logistic regression were used to estimate the ratios of relative risks (RRs) of outcomes of interest among patients with and without diabetes. A 95% CI that crosses 1.00 indicates that the effect of aspirin does not differ between patients with and without diabetes. RESULTS Nine RCTs with moderate to high methodological quality contributed data to the analyses. The ratios of RRs comparing the benefit of aspirin among patients with diabetes compared with patients without diabetes for mortality, myocardial infarction, and ischemic stroke were 1.12 (95% CI 0.92–1.35), 1.19 (0.82–1.17), and 0.70 (0.25–1.97), respectively. CONCLUSIONS Whereas estimates of benefit among patients with diabetes remain imprecise, our analysis suggests that the relative benefit of aspirin is similar in patients with and without diabetes.
Risk of Fracture After Single Fraction Image-Guided Intensity-Modulated Radiation Therapy to Spinal Metastases
Rose, Peter S. , Laufer, Ilya , Boland, Patrick J. , Hanover, Andrew, Bilsky, Mark H. , Yamada, Josh, Lis, Eric

Mayo Clinic

Journal of Clinical Oncology | September 9, 2009 | Volume: 27 | Issue: 30 | Pages: 5075-5079

10.1200/jco.2008.19.3508 | PMID 19738130 Get It

Purpose Single-fraction image-guided intensity-modulated radiation therapy (IG-IMRT) allows for tumoricidal treatment of traditionally radioresistant cancers while sparing critical adjacent structures. Risk of vertebral fracture after IG-IMRT for spinal metastases has not been defined. Patients and Methods We evaluated 62 consecutive patients undergoing single fraction IG-IMRT at 71 sites for solid organ metastases. A neuroradiologist and three spine surgeons evaluated prospectively obtained magnetic resonance/computed tomography (CT) imaging studies for post-treatment fracture development and tumor recurrence. Results Fracture progression was noted in 27 vertebrae (39%). Multivariate logistic regression analysis showed that CT appearance, lesion location, and percent vertebral body involvement independently predicted fracture progression. Lesions located between T10 and the sacrum were 4.6 times more likely to fracture than were lesions above T10 (95% CI, 1.1 to 19.7). Lytic lesions were 6.8 times more likely to fracture than were sclerotic and mixed lesions (95% CI, 1.4 to 33.3). As percent vertebral body involvement increased, odds of fracture also increased. Patients with fracture progression had significantly higher narcotic use, change in Karnofsky performance score, and a strong trend toward higher pain scores. Local tumor progression occurred in seven patients and contributed to one fracture. Obesity, posterior element involvement, bisphosphonate use, and local kyphosis did not confer increased risk. Conclusion Vertebral fracture is common after single fraction IG-IMRT for metastatic spine lesions. Lytic disease involving more than 40% of the vertebral body and location at or below T10 confer a high risk of fracture, the presence of which yields significantly poorer clinical outcomes. These results may help clinicians identify high-risk patients who would benefit from prophylactic vertebro- or kyphoplasty.
Candidate Gene Polymorphisms for Ischemic Stroke
Matarín, Mar, Brown, W. Mark , Dena, Hernandez, Britton, Angela, Vrieze, Fabienne Wavrant De, Brott, Thomas G. , Brown, Robert D., Worrall, Bradford B. , Case, L. Douglas, Metter, E. Jeffrey , Gamble, Dale M., Hardy, John , Rich, Stephen S. , Singleton, Andrew , Chanock, Stephen Jacob , Ferrucci, Luigi , Meschia, James F. , Rich, Stephen S , Hardy, John

Mayo Clinic

Stroke | September 4, 2009 | Volume: 40 | Issue: 11 | Pages: 3436-3442

10.1161/strokeaha.109.558015 | PMID 19729601 Get It

Background and Purpose— Ischemic stroke (IS) is a multifactorial disorder with strong evidence from twin, family, and animal model studies suggesting a genetic influence on risk and prognosis. Several candidate genes for IS have been proposed, but few have been replicated. We investigated the contribution of 67 candidate genes (369 single nucleotide polymorphisms [SNPs]) on the risk of IS in a North American population of European descent. Methods— Two independent studies were performed. In the first, 342 SNPs from 52 candidate genes were genotyped in 307 IS cases and 324 control subjects. The SNPs significantly associated with IS were tested for replication in another cohort of 583 IS cases and 270 control subjects. In the second study, 212 SNPs from 62 candidate genes were analyzed in 710 IS cases with subtyping available and 3751 control subjects. Results— None of the candidate genes (SNPs) were significantly associated with IS risk independent of known stroke risk factors after correction for multiple hypotheses testing. Conclusion— These results are consistent with previous meta-analyses that demonstrate an absence of genetic association of variants in plausible candidate genes with IS risk. Our study suggests that the effect of the investigated SNPs may be weak or restricted to specific populations or IS subtypes.
Quantifying Speech Rhythm Abnormalities in the Dysarthrias
White, Laurence , Lansford, Kaitlin L. , Lotto, Andrew J., Spitzer, Stephanie M., Caviness, John N., Liss, Julie , Mattys, Sven L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | August 28, 2009 | Volume: 52 | Issue: 5 | Pages: 1334-1352

10.1044/1092-4388(2009/08-0208) | PMID 19717656 Get It

Purpose In this study, the authors examined whether rhythm metrics capable of distinguishing languages with high and low temporal stress contrast also can distinguish among control and dysarthric speakers of American English with perceptually distinct rhythm patterns. Methods Acoustic measures of vocalic and consonantal segment durations were obtained for speech samples from 55 speakers across 5 groups (hypokinetic, hyperkinetic, flaccid-spastic, ataxic dysarthrias, and controls). Segment durations were used to calculate standard and new rhythm metrics. Discriminant function analyses (DFAs) were used to determine which sets of predictor variables (rhythm metrics) best discriminated between groups (control vs. dysarthrias; and among the 4 dysarthrias). A cross-validation method was used to test the robustness of each original DFA. Results The majority of classification functions were more than 80% successful in classifying speakers into their appropriate group. New metrics that combined successive vocalic and consonantal segments emerged as important predictor variables. DFAs pitting each dysarthria group against the combined others resulted in unique constellations of predictor variables that yielded high levels of classification accuracy. Conclusions This study confirms the ability of rhythm metrics to distinguish control speech from dysarthrias and to discriminate dysarthria subtypes. Rhythm metrics show promise for use as a rational and objective clinical tool.
Short- and Long-Term Risk Stratification Using a Next-Generation, High-Sensitivity Research Cardiac Troponin I (hs-cTnI) Assay in an Emergency Department Chest Pain Population
Kavsak, Peter A. , Ko, Dennis T. , MacRae, Andrew R., Jaffe, Allan S. , Wang, Xuesong , Jaffe, Allan S. , Kavsak, Peter

Mayo Clinic

Clinical Chemistry | August 13, 2009 | Volume: 55 | Issue: 10 | Pages: 1809-1815

10.1373/clinchem.2009.127241 | PMID 19679630 Get It

Abstract Background: The next-generation, high-sensitivity cardiac troponin assays can measure quantifiable concentrations of cTn in a majority of individuals, but there are few studies assessing these assays for risk stratification. The present study was undertaken to determine if a research hs-cTnI assay can be useful for predicting death/myocardial infarction (MI), both short- and long-term, in an emergency department acute coronary syndrome (ACS) population. Methods: In a cohort of 383 subjects, originally recruited in 1996, presenting to the emergency department with symptoms suggestive of ACS, the heparin plasma obtained at initial presentation was thawed and measured in 2007 with a research hs-cTnI assay. AccuTnI (Beckman Coulter) measurements were made on these same samples in 2003. The population was divided into 4 groups by hs-cTnI: &lt;5.00, 5.00–9.99, 10.00–40.00, and &gt;40.00 ng/L. Kaplan–Meier, Cox proportional hazards, ROC curves, and logistic regression analyses were used to identify which hs-cTnI concentrations were predictive of death/MI within 10 years after presentation. Results: There were significant differences between the hs-cTnI groups for the probability of death/MI up to 10 years after presentation (P &lt; 0.05). At 6 months, patients with hs-cTnI ≥10.00 ng/L were at higher risk for death/MI (hazard ratio &gt;3.7; P &lt; 0.05) compared with those having hs-cTnI &lt;5.00 ng/L. ROC curve analysis for death/MI at 30 days with the hs-cTnI assay had an area under the curve of 0.74 (95% CI 0.65–0.82), with logistic models yielding an optimal assay threshold of 12.68 ng/L. Conclusions: This research hs-cTnI assay appears useful for risk stratification for death/MI in an ACS population.